Date: 2014-10-16
Type of information: R&D agreement
Compound: drugs using Moderna\'s messenger RNA (mRNA) Therapeutics™ technology
Company: Moderna Therapeutics (USA - MA) Karolinska Institutet (Sweden) Karolinska University Hospital
Therapeutic area:
Type agreement: R&D development
Action mechanism: messenger RNA Therapeutics™ is a new in vivo drug technology that produces human proteins or antibodies inside patient cells, which are in turn secreted or active intracellularly. This breakthrough platform addresses currently undruggable targets and offers a superior alternative to existing drug modalities for a wide range of disease conditions.
Disease:
Details: * On October 16, 2014, Moderna Therapeutics announced a strategic, long-term collaboration with Karolinska Institutet (KI) and Karolinska University Hospital (KUH) for the discovery and development of innovative drugs using Moderna\'s messenger RNA (mRNA) Therapeutics™ technology. Under the terms of the partnership, Moderna will sponsor research grants for scientists at both institutions to conduct preclinical research with novel mRNA Therapeutics™. As this pre-clinical work is successfully completed, Moderna will conduct clinical trials of new drug candidates at Karolinska University Hospital. To solidify the scientific and clinical collaboration between the organizations, and to optimize the output of this important partnership, Moderna is creating a new laboratory in Stockholm, Sweden, located in the Novum building next to the Karolinska University Hospital Huddinge campus. \"Moderna is investing heavily to bring mRNA Therapeutics to patients, and our science is accelerating rapidly,\" said Stéphane Bancel, President and founding CEO of Moderna. \"This partnership puts our mRNA Therapeutics platform in the hands of Karolinska\'s world-class scientists and clinical researchers to develop new drugs and therapeutic approaches that cannot be done with small molecules or biologics – bringing new hope to patients with serious diseases.\" This agreement is Moderna\'s first academic partnership.
Financial terms:
Latest news:
